Erivedge
Erivedge ingredients
| Active ingredient | Strength |
|---|---|
| Vismodegib | 150 mg/1 |
What Erivedge is used for
The FDA lists the approved uses on the official label (below). In the EU, vismodegib is approved as Erivedge for:
Erivedge is indicated for the treatment of adult patients with:- symptomatic metastatic basal cell carcinoma- locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Erivedge
- Generic name
- Vismodegib
- Made by
- Genentech, Inc.
- Forms
- Capsule
- Given
- Oral
- Drug class
- Hedgehog Pathway Inhibitor
- FDA approval
- New drug application (NDA) NDA203388
- On the US market since
- 2012
Official information
- Erivedge prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Vismodegib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Erivedge?
Erivedge (Vismodegib) is a cancer medicine made by Genentech, Inc., approved by the US FDA.
What are the ingredients of Erivedge?
Erivedge contains Vismodegib (150 mg/1).
Is Erivedge approved in Europe?
The same active substance is approved in the EU as Erivedge.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA